EP2896613A4 - Sulfonamide compound - Google Patents

Sulfonamide compound

Info

Publication number: EP2896613A4
Authority: EP; European Patent Office
Prior art keywords: sulfonamide compound; sulfonamide; compound
Prior art date: 2012-09-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP13837919.3A

Other languages

German (de)

French (fr)

Other versions

EP2896613B1 (en

EP2896613A1 (en

Inventor

Taku Kato

Toshiaki Sakamoto

Akira Kubo

Daisuke Sawamoto

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Mitsubishi Tanabe Pharma Corp

Original Assignee

Mitsubishi Tanabe Pharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-09-14

Filing date

2013-09-13

Publication date

2016-02-24

2013-09-13 Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp

2015-07-22 Publication of EP2896613A1 publication Critical patent/EP2896613A1/en

2016-02-24 Publication of EP2896613A4 publication Critical patent/EP2896613A4/en

2018-03-21 Application granted granted Critical

2018-03-21 Publication of EP2896613B1 publication Critical patent/EP2896613B1/en

Status Active legal-status Critical Current

2033-09-13 Anticipated expiration legal-status Critical

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

EP13837919.3A 2012-09-14 2013-09-13 Sulfonamide compound Active EP2896613B1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2012203126		2012-09-14
JP2012203128		2012-09-14
PCT/JP2013/074812 WO2014042238A1 (en)	2012-09-14	2013-09-13	Sulfonamide compound

Publications (3)

Publication Number	Publication Date
EP2896613A1 EP2896613A1 (en)	2015-07-22
EP2896613A4 true EP2896613A4 (en)	2016-02-24
EP2896613B1 EP2896613B1 (en)	2018-03-21

Family

ID=50278343

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP13837919.3A Active EP2896613B1 (en)	2012-09-14	2013-09-13	Sulfonamide compound

Country Status (6)

Country	Link
US (1)	US9487488B2 (en)
EP (1)	EP2896613B1 (en)
JP (1)	JP6127056B2 (en)
ES (1)	ES2664977T3 (en)
TW (1)	TW201418221A (en)
WO (1)	WO2014042238A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20190017800A (en) *	2016-06-13	2019-02-20	미쓰비시 타나베 파마 코퍼레이션	Composition for the treatment or prevention of vasomotor symptoms
JP7032903B2 (en) *	2016-10-12	2022-03-09	田辺三菱製薬株式会社	Method for producing a sulfonamide compound
JP7265551B2 (en)	2017-12-19	2023-04-26	田辺三菱製薬株式会社	Compositions and methods for treating or preventing vasomotor symptoms
JP6985137B2 (en) *	2017-12-27	2021-12-22	田辺三菱製薬株式会社	Crystal form of sulfonamide compound

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR067602A1 (en)	2007-07-18	2009-10-14	Janssen Pharmaceutica Nv	SULFONAMIDE AS TRPM8 MODULATORS
WO2010010435A2 (en)	2008-07-22	2010-01-28	Glenmark Pharmaceutical S.A.	Fused oxazole and thiazole derivatives as trpms modulators
CA2747662A1 (en) *	2008-12-18	2010-07-15	Janssen Pharmaceutica Nv	Sulfonamides as trpm8 modulators
US20120094964A1 (en)	2009-05-01	2012-04-19	Tadashi Inoue	Sulfamoyl benzoic acid derivatives as trpm8 antagonists
TW201103941A (en)	2009-06-10	2011-02-01	Janssen Pharmaceutica Nv	Benzimidazole derivatives useful as TRPM8 channel modulators
US8829026B2 (en) *	2010-10-01	2014-09-09	Raqualia Pharma Inc.	Sulfamoyl benzoic acid heterobicyclic derivatives as TRPM8 antagonists
JP2013544894A (en) *	2010-12-09	2013-12-19	ヤンセンファーマシューティカエヌ．ベー．	Imidazo [1,2-A] pyridinesulfonamide as a TRPM8 modulator
AU2012229813B2 (en) *	2011-03-16	2015-09-03	Mitsubishi Tanabe Pharma Corporation	Sulfonamide compounds having TRPM8 antagonistic activity
US8900705B2 (en)	2011-11-16	2014-12-02	Cristal Usa Inc.	Mesoporous titanium dioxide nanoparticles exhibiting bimodal pore size distributions and process for their production
JP5985453B2 (en) *	2012-09-14	2016-09-06	田辺三菱製薬株式会社	Pharmaceutical composition

2013
- 2013-09-13 WO PCT/JP2013/074812 patent/WO2014042238A1/en active Application Filing
- 2013-09-13 EP EP13837919.3A patent/EP2896613B1/en active Active
- 2013-09-13 JP JP2014535601A patent/JP6127056B2/en active Active
- 2013-09-13 US US14/428,267 patent/US9487488B2/en active Active
- 2013-09-13 TW TW102133143A patent/TW201418221A/en unknown
- 2013-09-13 ES ES13837919.3T patent/ES2664977T3/en active Active

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO2014042238A1 *

Also Published As

Publication number	Publication date
TW201418221A (en)	2014-05-16
US20150307454A1 (en)	2015-10-29
WO2014042238A1 (en)	2014-03-20
JPWO2014042238A1 (en)	2016-08-18
ES2664977T3 (en)	2018-04-24
EP2896613B1 (en)	2018-03-21
EP2896613A1 (en)	2015-07-22
JP6127056B2 (en)	2017-05-10
US9487488B2 (en)	2016-11-08

Publication	Publication Date	Title
IL268013A (en)	2019-09-26	Tetrahydropyrazolopyrimidine compounds
HK1245780B (en)	2020-01-17	Imidazopyrrolidinone compounds
EP2842955A4 (en)	2015-09-16	Trk-INHIBITING COMPOUND
IL237341A0 (en)	2015-04-30	Pro-neurogenic compounds
GB201209138D0 (en)	2012-07-04	Compounds
HK1210146A1 (en)	2016-04-15	Substituted sulfonamide compounds
GB201214750D0 (en)	2012-10-03	Compounds
GB201215357D0 (en)	2012-10-10	Compounds
EP2887803A4 (en)	2016-08-03	Pro-neurogenic compounds
HK1206726A1 (en)	2016-01-15	Imidazotriazinone compounds
GB201220843D0 (en)	2013-01-02	Compound
GB201204985D0 (en)	2012-05-02	Compounds
GB201204125D0 (en)	2012-04-25	Compounds
HK1211283A1 (en)	2016-05-20	Compounds
GB201209096D0 (en)	2012-07-04	Compounds
HK1206356A1 (en)	2016-01-08	Lpar - substituted cyanopyrazole compounds lpar-
GB201219820D0 (en)	2012-12-19	Compounds
EP2896613A4 (en)	2016-02-24	Sulfonamide compound
GB201216309D0 (en)	2012-10-24	Compound
GB201215675D0 (en)	2012-10-17	Compound
GB201217310D0 (en)	2012-11-14	Compounds
GB201216448D0 (en)	2012-10-31	Compound
GB201222716D0 (en)	2013-01-30	Compound
GB201223429D0 (en)	2013-02-06	Compounds
GB201220029D0 (en)	2012-12-19	Compounds

Legal Events

Date	Code	Title	Description
2015-06-19	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2015-07-22	17P	Request for examination filed	Effective date: 20150323
2015-07-22	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2015-07-22	AX	Request for extension of the european patent	Extension state: BA ME
2015-08-19	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: MITSUBISHI TANABE PHARMA CORPORATION
2015-12-23	DAX	Request for extension of the european patent (deleted)
2016-02-24	RA4	Supplementary search report drawn up and despatched (corrected)	Effective date: 20160126
2016-02-24	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 25/04 20060101ALI20160120BHEP Ipc: C07D 413/14 20060101ALI20160120BHEP Ipc: A61P 15/00 20060101ALI20160120BHEP Ipc: A61K 31/5377 20060101ALI20160120BHEP Ipc: A61P 35/00 20060101ALI20160120BHEP Ipc: A61P 1/00 20060101ALI20160120BHEP Ipc: A61P 17/00 20060101ALI20160120BHEP Ipc: A61P 11/00 20060101ALI20160120BHEP Ipc: A61P 25/06 20060101ALI20160120BHEP Ipc: A61P 43/00 20060101ALI20160120BHEP Ipc: C07D 217/22 20060101AFI20160120BHEP Ipc: A61P 25/00 20060101ALI20160120BHEP Ipc: A61K 31/4725 20060101ALI20160120BHEP Ipc: A61P 13/00 20060101ALI20160120BHEP Ipc: C07D 401/14 20060101ALI20160120BHEP Ipc: C07D 401/12 20060101ALI20160120BHEP Ipc: A61K 31/472 20060101ALI20160120BHEP Ipc: C07D 413/12 20060101ALI20160120BHEP
2017-01-18	17Q	First examination report despatched	Effective date: 20161215
2017-10-23	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2017-11-22	INTG	Intention to grant announced	Effective date: 20171024
2018-02-12	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2018-02-16	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2018-03-21	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2018-03-21	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2018-03-21	RIN1	Information on inventor provided before grant (corrected)	Inventor name: SAKAMOTO, TOSHIAKI Inventor name: SAWAMOTO, DAISUKE Inventor name: KUBO, AKIRA Inventor name: KATO, TAKU
2018-03-29	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2018-04-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 980923 Country of ref document: AT Kind code of ref document: T Effective date: 20180415
2018-04-18	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2018-04-19	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602013034842 Country of ref document: DE
2018-04-24	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2664977 Country of ref document: ES Kind code of ref document: T3 Effective date: 20180424
2018-07-25	REG	Reference to a national code	Ref country code: NL Ref legal event code: MP Effective date: 20180321
2018-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180321 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180321 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180321 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180321 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180621
2018-08-10	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG4D
2018-08-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 980923 Country of ref document: AT Kind code of ref document: T Effective date: 20180321
2018-08-28	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 6
2018-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180321 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180622 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180621 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180321 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180321
2018-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180321 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180321 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180321 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180321 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180321
2018-11-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180321 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180321 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180321 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180321
2018-12-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180723
2019-01-02	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602013034842 Country of ref document: DE
2019-01-25	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2019-01-25	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2019-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180321
2019-02-27	26N	No opposition filed	Effective date: 20190102
2019-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180321
2019-04-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2019-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180321
2019-06-12	REG	Reference to a national code	Ref country code: BE Ref legal event code: MM Effective date: 20180930
2019-06-26	REG	Reference to a national code	Ref country code: IE Ref legal event code: MM4A
2019-06-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180913
2019-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180913
2019-08-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180930 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180930 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180930
2020-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180913
2020-03-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180321
2020-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20130913 Ref country code: MK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180321
2020-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180721
2023-06-14	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230510
2024-01-22	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: ES Payment date: 20231003 Year of fee payment: 11
2024-10-10	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DE Payment date: 20240730 Year of fee payment: 12
2024-10-14	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20240801 Year of fee payment: 12
2024-10-16	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20240808 Year of fee payment: 12
2024-10-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IT Payment date: 20240812 Year of fee payment: 12